Retinoic acid (RA) signaling in vertebrate embryos occurs in a distinct physical and temporal pattern. Regulating this spatial distribution is crucial to the development of the embryo, as RA in excess or in inappropriate tissues is teratogenic. In order to understand how RA availability is determined in zebrafish we have investigated the expression of cyp26a1, an enzyme that inactivates RA, and its relationship to raldh2, one of the enzymes that produce RA from retinal. cyp26a1 expression follows three phases: in presumptive anterior neurectoderm and in a circumblastoporal ring during gastrulation, in the tailbud throughout somitogenesis, and in multiple specific tissue types beginning at mid-somitogenesis and continuing through 48 h postfertilization (hpf). This expression was either adjacent or opposite to those tissues expressing raldh2. We then investigated how RA production might regulate these relationships. Endogenous RA produced by raldhs did not play a role in setting cyp26a1 expression in most tissues. However, exogenous RA regulates expression of both enzymes. cyp26a1 is up regulated in the embryo in a time, concentration, and tissue-dependent manner. Conversely, raldh2 expression is reduced with RA treatment. Tests of the raldh2 promoter in cell transfections proved that RA directly represses its activity. These data demonstrate that the feedback mechanisms regulating production and degradation of RA must be considered in any experiments altering levels of RA in the developing vertebrate embryo.
Introduction
Retinoic acid (RA), a metabolite of vitamin A, has proven to be necessary for the proper development of the vertebrate embryo. Embryos deficient in vitamin A (vitamin A deficiency syndrome or VAD) fail to complete development and demonstrate patterning defects in the CNS, circulatory system, hematopoietic system, limbs, and trunk (reviewed by, Maden, 2000; Ross et al., 2000; Zile, 2001) . In contrast, when RA is available to embryos in the wrong places or at the wrong times it is a potent teratogen (Shenefelt, 1972) . Given the potential for developmental defects when RA is either absent or in excess, a mechanism must be in place to create the appropriate pattern of RA activity. Localizing RA availability via the enzymes that produce and degrade it creates the needed balance of RA signaling.
RA acts by regulating transcription through the retinoic acid receptors (RARs) and retinoid X receptors (RXRs) (Brand et al., 1988; Bugge et al., 1992; Giguere et al., 1987; Kliewer et al., 1992; Mangelsdorf et al., 1990; Petkovich et al., 1987; Zhang et al., 1992) . Both receptors have multiple types and each type is found in multiple isoforms. Together the nuclear receptors form a RAR/RXR heterodimer on a retinoic acid response element (RARE) in the regulatory regions of target genes and when bound to RA initiate transcription (de The et al., 1990; Heery et al., 1993; Leid et al., 1992; Marks et al., 1992) (reviewed, Chambon, 1996) . With the discovery of the RA receptors, their localization seemed to be the key in explaining how the embryo limits RA signaling to the appropriate spatial and temporal pattern. However, targeted disruption of the RARs and RXRs in mice results in complex phenotypes and analysis suggests functional redundancy (reviewed, Conlon, 1995; Kastner et al., 1995) . These results indicate that RARs, while necessary, are not the limiting factor in creating the pattern of RA activity.
Alternatively, the availability of RA itself seems to play a more prominent role in setting signaling boundaries. The production of RA is dependent on the two-step conversion of vitamin A (retinol) to retinal in a rate-limiting reaction, and then from retinal to RA in an irreversible oxidation (Dowling and Wald, 1960; Duester, 1996; Napoli, 1996) . Regulating the spatial and temporal expression of the enzymes that oxidize these precursors could, in effect, limit the pattern of RA induced transcription (Maden, 1999; Swindell et al., 1999) . Three members of the aldehyde dehydrogenase family have been found to have high specificity for retinal: raldh1, raldh2, and raldh3. While raldh1 and raldh3 are expressed in a limited number of sites, raldh2 is more broadly expressed (Begemann et al., 2001; Chen et al., 2001; Grandel et al., 2002; Haselbeck et al., 1999; Li et al., 2000; McCaffery et al., 1992; Mic et al., 2000; Niederreither et al., 1997; Suzuki et al., 2000; Swindell et al., 1999; Zhao et al., 1996) . Localization of raldh2 throughout embryonic development is found at or adjacent to many areas of transgene activity in animals designed to express reporter genes responding to RA signaling (Balkan et al., 1992; Mendelsohn et al., 1991; Perz-Edwards et al., 2001; Reynolds et al., 1991) . These facts suggest that raldh2 expression might be key to creating the RA signaling pattern.
Disruption of the raldh2 gene in mouse demonstrates that RA is not only critical for development, but also that this one gene is responsible for the majority of RA production in the embryo. Raldh2 2 /2 mice strongly resemble VAD fetuses. They die midgestation without turning, with shortened bodies, no limb buds, a dilated heart, missing posterior branchial arches, and severe defects in patterning of the hindbrain and heart (Mic et al., 2002; Niederreither et al., 1999 Niederreither et al., , 2000 Niederreither et al., , 2001 . Similar phenotypes have been reported in mutations of raldh2 in zebrafish. Homozygote embryos of two separate raldh2 mutant lines, neckless (nls) and no-fin (nof), share defects in hindbrain patterning, lack of pectoral fins, and missing gill arches (Begemann et al., 2001; Grandel et al., 2002) .
Controlling raldh localization is not the only critical factor in creating defined areas of RA signaling. Tissues sensitive to RA teratogenesis often lie close to areas of RA production. Since RA diffuses easily (Eichele and Thaller, 1987) , a mechanism must be in place to ensure that RA does not initiate transcription in these areas. A candidate for this regulatory role was found when cytochrome P450RAI 26 (cyp26a1) was identified as a RA-inducible gene that catalyzes the conversion of RA to oxidized derivatives (Fujii et al., 1997; Ray et al., 1997; White et al., 1996) . It seems plausible that a metabolizing enzyme that alters RA so that it is no longer active in signaling can provide the balance to RA production.
Expression analysis in various species supports this idea that cyp26a1 plays a role in regulating RA activity.
These studies show that cyp26a1 is expressed in areas such as the anterior neural tube and tailbud, both known to be sensitive to RA teratogenesis (de Roos et al., 1999; Fujii et al., 1997; Hill et al., 1995; Holder and Hill, 1991; Hollemann et al., 1998; Iulianella et al., 1999; Kudoh et al., 2002; Padmanabhan, 1998; Shum et al., 1999; Swindell et al., 1999) . In addition, double in situ hybridization analysis in chick showed that cyp26a1 expression during gastrulation was in tissues opposite to those expressing raldh2 (Swindell et al., 1999) .
Thus, it has been demonstrated that cyp26a1 oxidizes RA and is expressed in areas sensitive to RA teratogenesis. However, the possibility remains that oxidized RA can bind RA receptors in the conventional RA signaling pathway or signal through another mechanism. In Xenopus, over expressing cyp26a1 mRNA causes phenotypes resembling RA deprivation. Also, over expression of cyp26a1 can rescue embryos from teratogenesis caused by RA treatment (Hollemann et al., 1998) . Both results would be expected only if cyp26a1 inactivates RA. Analysis of cyp26a1 knockout mice also supports this hypothesis. In Cyp26a1 2/2 mice, RA signaling is expanded anteriorly into the hindbrain and posteriorly into the tail (Abu-Abed et al., 2001; Sakai et al., 2001) . Further proof comes from a later study demonstrating that in Raldh2 þ /2, Cyp26a1 2 /2 mouse embryos many of the defects seen in Cyp26a1 2 /2 fetuses are suppressed. (Niederreither et al., 2002) . Here, reducing RA levels genetically is enough to compensate for the excesses found in Cyp26a1 2 /2 mice. Together these results support the hypothesis that cyp26a1 functions to create boundaries to areas of RA signaling (reviewed, Maden, 1999) .
In this study, we investigate how areas of RA signaling are set by expression of raldh2 and cyp26a1 in the zebrafish embryo. We detail the expression of cyp26a1 through the first 48 h postfertilization (hpf) and compare its expression to that of raldh2. We also show that RA influences its own metabolism through feedback regulation of both cyp26a1 and raldh2. These data show that the response of the embryo to RA challenge must be considered in the context of changing enzyme expression levels and patterns, which are specific to the age of the embryo and timing of treatment.
Results

Expression pattern of cyp26a1
Three phases of cyp26a1 expression are found in the first few days of zebrafish development. Initially, during gastrulation and early somitogenesis, cyp26a1 is expressed in the presumptive anterior neural ectoderm and around the blastoderm margin (Fig. 1A,B) (Kudoh et al., 2002) . Anterior expression excludes the presumptive notochord region (Fig. 1B, black arrow) . As convergent extension progresses the anterior expression narrows until cyp26a1 is found in two bands corresponding to the presumptive forebrain and the midbrain at three somites (S) (Fig. 1 compare B,D,E) after which point this anterior expression is no longer seen. This sets up the second phase that is marked by strong expression in the tailbud. While we first find expression in the tailbud as it forms at the bud stage (Fig. 1C) , it continues throughout somitogenesis even after the anterior expression seen through 3S is gone (Fig. 1F,G,I ). During this stage, we also see expression in the ventral portion of somite boundaries (Fig. 1G) , in the developing branchial arches (Fig. 1F ,H,J,L), and in the caudal portion of the notochord (Fig. 1I ). This stage ends at 24hpf (Fig. 1I) , when we last see expression in the tailbud. After somitogenesis, cyp26a1 is expressed in specific tissues of the embryo. By 30hpf (Fig. 1J) , cyp26a1 expression remains in the branchial arches, and is now seen in the neural retina (Fig. 1K ). At 48hpf (Fig. 1L) , cyp26a1 is also seen at the base of the pectoral fin and in small area on each side (left/ right) of the posterior hindbrain. In sum, patterns of cyp26a1 expression reveal that development of tissues such as the neural ectoderm, branchial arches, eye, and tail likely require an absence of RA signaling.
RA production is closely apposed to RA degradation
Comparing expression patterns of cyp26a1 and raldh2 demonstrates that these genes are produced both in tissues that are at opposite ends of the axis and in tissues directly adjacent to one another. Early in development, cyp26a1 is is found in the presumptive neural plate and around the blastoderm margin, but is excluded from the presumptive notochord region (B, black arrow). (C-E) cyp26a1 expression in the presumptive neural tube condenses, forming two bands of expression corresponding to the presumptive forebrain (fb) and midbrain (mb). At bud stage (C,D) we also see a band of expression in the middle portion of the embryo (black asterisk). (C,F,G,I) cyp26a1 is expressed in the tailbud throughout growth of the tail. By 24hpf (I) cyp26a1 is down regulated in the trunk and tail. During somitogenesis cyp26a1 is expressed in the ventral boundary of somites (G, white arrowheads), in the developing branchial arches (F,H,J, white arrow), and in the posterior notochord (I, black arrow). Post-somitogeneis expression of cyp26a1 initiates in the neural retinal (K r, retina, l, lens), base of the pectoral fin (L, white asterisk), and cells in the hindbrain (L, black arrowhead).
found in the presumptive neural ectoderm, while raldh2 is localized in the presumptive mesendoderm ( Fig. 2A) . Thus, an area of RA degradation is in the anterior of the embryo while an area of RA production is in the posterior with the intervening area free of either activity. In contrast, at the same stage, the two genes are also expressed in neighboring tissues. cyp26a1 has a second site of expression in the epiblast of the posterior margin (Fig. 1A ) very near the raldh2 expression ( Fig. 2A) . This same type of close association is seen in the posterior of the embryo during somitogenesis. During this period raldh2 is expressed in the developing somites, while cyp26a1 is expressed in the tailbud region (Fig. 2B,C) . At the 3S stage, a flatmount reveals that cyp26a1 is found in cells adjacent to both the anterior and posterior limits of raldh2 expression (Fig. 2D ). As somitogenesis progresses there is a larger gap between the two genes ( Fig. 2E , bracket). By 24hpf (Fig. 2F) , somitogenesis has completed and we see a concurrent reduction in the expression of both genes in the trunk and tail of the embryo. Later, we see close association of cyp26a1 and raldh2 in the developing branchial arches (Fig. 2G,H) . By 48hpf, raldh2 is expressed in the lateral aspect of the arches, while cyp26a1 is found more medially (Fig. 2I ). These comparisons demonstrate that cyp26a1 expression is most often found in cells in close association to cells producing RA.
Production of RA via raldhs is not required for expression of cyp26a1
RA itself may regulate the expression of cyp26a1 in cells near and adjacent to raldh2 expression. Previous study of the cyp26a1 promoter region (Loudig et al., 2000) suggests that cyp26a1 expression may be controlled by the presence of retinoic acid. To address this question we examined the expression of cyp26a1 both in embryos treated with an inhibitor of raldhs, diethylaminobenzaldehyde (DEAB) and in embryos injected with a morpholino against raldh2. We saw no change in cyp26a1 during gastrulation in either embryos treated with the inhibitor or in embryos injected with the morpholino (data not shown). Expression of cyp26a1 also remained in the tailbud during somitogenesis, as seen in raldh2 knockdown embryos at 5S (Fig. 3A ,B) and in DEAB treated embryos at 20S (Fig. 3C,D) . We did note, however, that DEAB treated embryos were missing expression of cyp26a1 in the somites. Thus, production of , cyp26a1 is expressed in the presumptive anterior neural plate, while raldh2 is expressed in the posterior involuted mesendoderm. As the tail bud forms, bud stage (B) and 3S (C), expression of cyp26a1 in the tail bud is adjacent to raldh2 in the presomitic mesoderm. cyp26a1 is also expressed just anterior to raldh2 (C, asterisk). cyp26a1 expression bounds expression of raldh2 in both the anterior and posterior of the 3S embryo (D) as seen in a flatmount. The distance between cyp26a1 expression in the tail bud and raldh2 in the somites increases with time (E, bracket). By 24hpf (F), both genes are being down regulated in the trunk and tail. cyp26a1 and raldh2 turn on concurrently in the developing branchial arches (G,H). A ventral view (yolk removed) of a 48hpf embryo shows that cyp26a1 and raldh2 have abutting expression in the branchial arches (I, arrow).
RA via raldh2 is not required to set cyp26a1 expression in either the anterior neural tube or the tail bud.
Exogenous RA induces cyp26a1 in a time, tissue and concentration dependent manner
In contrast to our results showing that endogenous RA was not required for most cyp26a1 expression, we found a strong induction of cyp26a1 in embryos challenged with exogenous RA. Embryos treated during gastrulation with increasing concentrations of RA demonstrated an expansion of the cyp26a1 expression zone posteriorly and into the presumptive notochord region (Fig. 4A -C ). Yet, we never saw expansion into the ventral portion of the embryo (Fig. 4D -F) . Similar RA treatments at later stages yielded inductions in regions of the embryo that did not normally express cyp26a1 (Fig. 4G -I) . Also, the regions expressing cyp26a1 expanded with concentration. At 10 27 M RA, cyp26a1 was induced in the eye, posterior hindbrain, midbrain, and anterior spinal cord (Fig. 4H) . Increasing the treatment concentration to 10 26 M RA resulted in induction throughout most of the anterior neural tube, excluding only the forebrain (Fig. 4I) . While cyp26a1 is induced in the posterior mesoderm, it is not induced in the neural tube at the same level. Neither do we ever see expression of cyp26a1 in the anterior trunk. Thus, in each tissue there seems to be a different threshold level for RA induction of cyp26a1 with some tissues apparently completely resistant to such inductions.
Next, we sought to better understand what might be setting the induction pattern of cyp26a1 in RA-treated embryos. One possibility is that cyp26a1 induction is regulated solely by its RARE. To investigate this question we compared the cyp26a1 in situ pattern to the pattern of a RA responsive transgenic line. This transgenic line expresses Yellow Fluorescent Protein (YFP), driven by RAREs, as a reporter of RA signaling activity (Perz-Edwards et al., 2001) . No induction of cyp26a1 is seen in the anterior trunk region of the embryo (Fig. 4H,I arrow) . This is true even when embryos are bathed in RA at 10 26 M from shield stage through to 24hpf (data not shown). In contrast, the RA responsive transgenic shows a very different pattern of induction. DMSO treated controls have expression only in the anterior spinal cord (Fig. 4J ). Embryos treated with 10 27 M RA have additional YFP expression throughout the anterior neural tube. In the corresponding cyp26a1 in situ we find that while induction occurs in the eyes, midbrain, and anterior hindbrain, we do not see induction in the forebrain and anterior hindbrain as seen in the transgenic fish (Fig. 4H,K) . At 10 26 M RA YFP is still not expressed in the somites where cyp26a1 is strongly induced (Fig. 4I ,L arrowheads). Altogether, these experiments have shown that exogenous RA regulates cyp26a1 expression very differently than does endogenous RA. This inductive response overlaps, in part, with the response of our RARE transgenic to exogenous RA. Other factors regulating cyp26a1 expression must moderate the activity of the promoter during RA induction to explain these differences.
raldh2 expression is directly repressed by retinoic acid
A previous study has shown that nls embryos, lacking fully functional raldh2 and thus producing less RA, showed an up-regulation of raldh2 in situ expression (Begemann et al., 2001 ). This suggests that there is a negative feed back loop regulating RA production. In order to determine if this is a direct effect upon the raldh2 promoter, we isolated the zebrafish raldh2 promoter region from a BAC clone containing the raldh2 gene. To test the response of the promoter region to RA, a reporter construct linking the raldh2 promoter region to firefly luciferase was created. This construct was transfected into zebrafish ZF-4 or AB cells along with zebrafish RARa and a control SV40 renilla luciferase plasmid. Adding 10 26 M RA significantly decreased the ratio of raldh2 promoter activity to that of the control (Fig. 5M ). This repression is consistent in both short (24hpf) and long (48hpf) RA exposures and in different cell lines, compare ZF-4 to AB (Table 1) . Thus, the data support a direct effect of RA upon raldh2 expression.
Considering these data, we sought to examine repression of raldh2 in the developing embryo. Again, we saw a clear inhibition of raldh2 with RA treatment. Repression of raldh2 expression is not uniform, rather it was lost in all but the most anterior somites and in the presumptive branchial arch region, in embryos treated from bud to 10S stages ( Fig. 5D -F) . Somites missing raldh2 expression still formed normally in treated embryos (Fig. 5A -C , white arrow). Patterns seen with both 10 27 M RA and 10 26 M RA treatments were very similar. At 10 27 M RA, only 3 -4 somites had raldh2 expression, while at 10 26 M RA 2-3 somites had raldh2 expression (Fig. 5G -I) . Also, raldh2 expression in anterior somites was reduced in intensity. Similar results are generated in embryos treated for a shorter period of time, 6S-10S (Fig. 5J-L) . Again, we see loss of raldh2 expression, although in fewer somites. Together these data demonstrate that raldh2 can be repressed by RA in vivo and that there are variances in the sensitivity of each somite to this repression along the anterior posterior axis of the embryo.
Discussion
Previous research in this lab focused on visualizing RA signaling in the developing vertebrate embryo via transgenesis (Balkan et al., 1992; Perz-Edwards et al., 2001) . We have undertaken a detailed study of the expression of cyp26a1 and its relationship to that of raldh2 in order to better understand how the pattern of RA signaling in the zebrafish embryo is determined. During somitogenesis we note coordination of strong expression of raldh2 in somites, the concurrent expression of cyp26a1 in the tailbud, and the subsequent down-regulation of both genes with 
L). Embryos were treated starting at sphere through 90% epiboly (A-F) and bud through 10S (G -L). (A-C) dorsal views, anterior top. (D -E) dorsal right, anterior top. (G -L) anterior left, dorsal top. (A-C)
cyp26a1 expression is progressively expanded posteriorly and into the presumptive notochord (black arrow) with increasing concentrations of RA. (D-F) cyp26a1 is never seen in the ventral portion of the embryo. In older embryos (10S, G-I) cyp26a1 is induced in the eye, anterior neural tube, and is expanded anteriorly into the somites. Expression is never induced in the trunk area (white arrow), telencephalon (asterisk), or in the posterior neural tube. Fluorescent pictures are RA responsive transgenics expressing YFP, white bar represents 100 mm (J -L). YFP expression is seen in the trunk (white arrow J-L) at all concentrations, but not in the somites (white arrowhead). mb, midbrain; ph, posterior hindbrain; asc, anterior spinal cord. RA treatment results in an accumulation of cells at the tailbud (C, black arrowhead). Expression of raldh2 is down regulated in 6 to 8 total somites and is lost in the presumptive branchial arch (ba) region with RA treatment for four hours, from bud to 10S (compare D to E,F and G to H,I). Down regulation of raldh2 in the somites is also seen with two-hour exposures to RA (compare J to K,L). (M) Regulation of the raldh2 promoter by RA as revealed by dual firefly/renilla luciferase assays in ZF4 cells exposed to RA for 48 h. Columns represent the ratio of raldh2 promoter firefly luciferase activity to SV40 renilla luciferase activity as a percentage of the DMSO control. Error bars represent standard deviation. An unpaired t-test shows that activity after treatment at 10 26 M RA is significantly different than in control treated cells P , 0:0001 (double asterisk). the completion of somitogenesis. This pattern sets strict boundaries between cells requiring an RA free area in the tailbud and those requiring RA activity after leaving the tailbud. Consistent with this hypothesis, we find feedback mechanisms are in place to maintain homeostasis of RA signaling. The embryo coordinates induction of cyp26a1 and repression of raldh2 upon challenge with excess RA. These data confirm that both genes are individually regulated by RA, but also reveal symmetry in this response. We also find that changes in gene expression vary with RA concentration, tissue, and the age of the embryo. The regulation of raldh2 by RA is direct, as our data show that RA represses the promoter of raldh2. Taken together our study demonstrates that embryos regulate RA availability differently depending upon tissue type and developmental time.
3.1. cyp26a1 and raldh2 expression patterns are consistent with RA signaling boundaries Our in situ hybridization analysis of cyp26a1 expression in zebrafish is consistent with its role as an enzyme that inactivates RA for signaling. It is found in areas where ectopic RA causes developmental defects, such as the tailbud. Also, it is excluded from areas that require RA signaling, such as the posterior neural tube. Our analysis is consistent with previously published patterns in mouse, chick, Xenopus, and expression analysis in zebrafish that was documented from 50% epiboly to the 3S stage. (Blentic et al., 2003; de Roos et al., 1999; Fujii et al., 1997; Hollemann et al., 1998; Kudoh et al., 2002; Swindell et al., 1999) . In all models there is strong expression in the dorsal anterior portion of the embryo during gastrulation and in the tailbud throughout the development of the tail. However, we also found a few significant exceptions to the patterns found in other species. A previous study has shown that cyp26a1 is expressed in a band dividing the eye into dorsal and ventral portions in the mouse (McCaffery et al., 1999) . McCaffery and colleagues McCaffery et al., 1999) have proposed that cyp26a1 functions to create a boundary between an area of low RA concentration in the dorsal retina and an area of high RA concentration in the ventral retina. However, in zebrafish, cyp26a1 in the eye was found in cells at various points around the circumference of the retina rather than in a band across the eye (Fig. 1K) . Therefore, it seems that cyp26a1 plays a different role in the development of the zebrafish eye than it does in the mouse eye. Expression of cyp26a1 in the eye of the chick is also very different, as it is found in the dorsal lens (Blentic et al., 2003) . Additionally, we do not see expression in rhombomere 2 of the hindbrain at any time, as was seen in mouse and chick (Blentic et al., 2003; Fujii et al., 1997; Swindell et al., 1999) . Neither do we see expression in the pectoral fin bud at the initial stages of outgrowth as was seen in the forelimb of other models (de Roos et al., 1999; Fujii et al., 1997; Swindell et al., 1999 ). The differences in cyp26a1 expression we see amongst different vertebrate species may be explained by the presence of additional cyp26 genes. One such gene, cyp26b1, has already been found in mice and has the same biochemical activity as cyp26a1 . Expression analysis of this gene in zebrafish reveals that it is expressed in both the hindbrain and pectoral fin (Linney lab, unpublished results) . Thus, the specific cyp26 acting within a tissue may vary from species to species.
Our direct comparison of cyp26a1 and raldh2 expression illustrates the role both genes play in forming functional boundaries of RA signaling. We found that the relationship between their patterns of expression is different in the anterior versus the posterior of the embryo. In gastrulating embryos we find cyp26a1 expressed in the presumptive anterior neurectoderm and raldh2 adjacent to the posterior neurectoderm ( Fig. 2A) . This pattern is similar to those described previously in chick and zebrafish (Kudoh et al., 2002; Swindell et al., 1999) . We note that these enzymes are also closely associated in the developing tailbud throughout somitogeneis. At the 3S stage, cells expressing cyp26a1 are in direct contact with cells expressing raldh2 in the developing mesoderm both anterior to the presomitic mesoderm and at the level of the tailbud (Fig. 2D) . This is an interesting situation as cells that likely require RA are closely situated to cells that are teratogenized by RA. There is a distinct switch as cells move from the RA free tailbud to the trunk region where RA signaling is strong. A similar situation is seen in the developing branchial arches, as once again the two genes are expressed adjacent to one another (Fig. 2I ). This suggests that tight spatial control of RA signaling is important in the development of the tail and the branchial arches.
Feedback mechanisms regulate enzyme expression during RA challenge
One possible mechanism for controlling the expression of cyp26a1 and raldh2 is a RA feedback loop. Yet, our analysis of cyp26a1 in embryos treated with an inhibitor of RA synthesis and in raldh2 'knockdown ' fish showed little change in its expression. Thus, other factors must set its expression during normal development. However, our data do support an important role for feedback mechanisms in embryos facing abnormal levels of RA, as both genes showed strong and also opposite responses to RA treatment.
Treatment with exogenous RA during gastrulation resulted in a simple expansion of cyp26a1 along the anterior -posterior axis of the embryo, similar to previous reports (Fig. 4A -F) (de Roos et al., 1999; Hollemann et al., 1998; Kudoh et al., 2002; Swindell et al., 1999) . However, we found more complex patterns of induction of cyp26a1 with RA treatment at later times. In embryos treated at the onset of somitogenesis we see both expansion of cyp26a1 from the tailbud into the somitic mesoderm and induction of cyp26a1 in the anterior neural tube (Fig. 4H,I ). Thus, we see induction of cyp26a1 in tissues that would not normally express the gene at this time. These cells that do not normally see RA retain the ability to initiate its metabolism to inactive forms. In addition, we find that the extent of ectopic cyp26a1 expression depends on the concentration of RA. As the only known function of cyp26a1 is to inactivate RA, it seems likely that those tissues showing an induction of cyp26a1 at lower RA concentrations are more sensitive to RA teratogenesis at the time of treatment.
RA signaling alone is not responsible for setting these patterns of cyp26a1 induction, as our indicator transgenic line shows that the induction pattern of YFP does not fully match that of cyp26a1. Another explanation for the differences in the cyp26a1 and YFP induction patterns may be the context of the enhancer elements in the respective promoters. Oosterveen et al. (2003) have shown that the activity of a particular RARE can vary with the specific sequence of the half site and also with the direct context of the RARE. This can result in differential sensitivity to RA.
We have also noted that certain tissues are resistant to induction of cyp26a1. The anterior trunk of the embryo never expresses cyp26a1 under any of the RA treatment conditions tried (Fig. 4G -I ) including treatment at 10 26 M RA from shield to 24hpf (data not shown). Therefore, a simple explanation for the pattern of induced cyp26a1 expression is unlikely. Our data suggest that cyp26a1 transcription is regulated in one of three ways, depending on the tissue. First, endogenous expression is mainly independent of RA for transcription. Second, cyp26a1 is inducible in additional tissues when challenged by excess RA. Third, in certain tissues, cyp26a1 is not found endogenously and is resistant to induction by RA. We suspect a complex interaction of signaling pathways sets what type of cyp26a1 regulation occurs in a specific tissue at a specific time.
We have also investigated RA regulation of raldh2 expression. We are the first to demonstrate that downregulation of raldh2 is a direct effect on its promoter. Niederreither et al. (1997) previously found raldh2 to be down-regulated in mouse embryos exposed to RA. However, they speculated that the effect was not direct as no changes in expression were seen until more than 6 h after administration of the RA by oral gavage. Perhaps this lag time can be explained in part by the indirect administration of RA in mouse, whereas zebrafish can be exposed directly to RA.
Taken together the responses of cyp26a1 and raldh2 to RA challenge are more informative than analysis of either separately. The induction of cyp26a1 and repression of raldh2 can be directly compared in embryos treated with 10 26 M RA from bud to 10S stages (Figs. 4I,5F ). Two things are clear in this comparison. First is the co-ordinate up-regulation of cyp26a1 and down-regulation of raldh2 in the posterior trunk and tail. Both serve to reduce RA signaling and are likely to prevent mis-patterning of developing structures that normally see no or low concentrations of RA. Second, cyp26a1 induction is excluded from the anterior somitic mesoderm, while raldh2 expression is maintained in this same area. Maintenance of raldh2 expression may be due to a higher endogenous level of transcript in this area. Analysis of our RARE transgenic supports this argument. We see expression of the transgene first in areas adjacent to the first few somites. Also, this fits well with a requirement for RA signaling in the anterior somitic region for pectoral fin outgrowth. Grandel et al. (2002) have demonstrated that RA is required for initiation of the pectoral fin bud prior to somitogenesis and is required for complete outgrowth of the fin through mid-somitogenesis at the level of the first few somites. Altogether, our results show that the embryo demonstrates a coordinated response to maintain homeostasis of RA signaling.
We have documented the complex and tissue specific regulation of RA metabolism in the zebrafish embryo. These analyses show that the pattern of RA availability within the developing embryo is highly dynamic and tightly regulated by RA itself. Monitoring levels of raldhs and cyp26s during manipulations of embryonic development gives insight into the relative concentrations of RA signaling that occurs in different tissues and cell types. These differences in concentration can be critical to patterning decisions as genes vary in their sensitivity to RA. Future study of these metabolizing enzymes may provide further evidence that the relative balance of raldh and cyp26 expression determines the absolute level of RA signaling in specific tissues. These patterns may explain the highly refined response of the embryo to RA signaling.
Experimental procedures
4.1. Whole-mount in situ hybridization and cloning of cyp26a1 probe A 769 bp fragment of zebrafish cyp26a1 was cloned from a 30-day-old zebrafish plasmid library into the pGem-T vector (Promega) using primers based upon the published sequence: 5 0 primer-TGG GCT TGC CGT TCA TTG G and 3 0 primer-GCA GTG CTG GCG GTG GTT TC. Sense and antisense riboprobes for cyp26a1 and raldh2 were synthesized with T7 and SP6 RNA polymerases as recommended by Roche.
Embryos were raised at 28.5 8C and staged according to Kimmel et al. (1995) . In situ hybridization was then performed as previously described (Oxtoby and Jowett, 1993) with the following exceptions. Proteinase K was used only on embryos older than 24hpf. Pre-hybridization was carried out for at least 4 h at 60 -65 8C. Hybridization was carried out overnight with probes at a concentration of approximately 1.5 mg/ml. Embryos were blocked for 1 h at room temperature and incubated with anti-digoxigenin alkaline phosphatase conjugated antibody (Roche) at 4 8C overnight. A blue color precipitate was produced by reacting with nitroblue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyphosphate (BCIP) as recommended by Roche. Embryos were mounted in either a 2:1 solution of benzyl benzoate: benzoic acid or 3% methyl cellulose.
In the case of double in situ hybridizations, the protocol of Liang et al. (2000) was used. In brief, we labeled the probes with fluorescein and digoxigenin. The first probe was developed using NBT/BCIP and the second was developed using p-ido nitrotetrayolium violet (INT)/BCIP, which produces an orange/red stain. Our protocol differed from the published protocol only in that we substituted PBT (phosphate buffered saline with 0.1% Tween-20) for MABT (100 mM maleic acid, 150 mM NaCl, 0.1% Tween-20, pH 7.5) in all of the wash steps and our blocking buffer was 2 mg/ml BSA, 5% sheep serum, and 1%DMSO in PBT. All images of in situ hybridizations were captured with a Nikon Coolpix 990 digital camera.
Retinoic acid (RA), diethylaminobenzaldehyde (DEAB) treatments, and fluorescence microscopy
All-trans-RA stocks were made at 10 23 M, 10 24 M, and 10 25 M in DMSO and stored at 2 80 8C for up to 1 month. DEAB was made as a 10 23 M stock in DMSO. Treatments were performed as previously described (Perz-Edwards et al., 2001) . DMSO was always kept at a final concentration of 0.1%. Transgenic fish carry a construct containing three RAREs and a GATA-2 minimal promoter driving YFP (Perz-Edwards et al., 2001) . Live RA-treated transgenic embryos were visualized with a Nikon TE300 microscope using laser scanning confocal microscopy. With Nikon EZ-C1 software, optical stacks were captured and maximum projections were created.
Morpholino injections
To knockdown raldh2 expression one morpholino (5 0 -gtt caa ctt cac tgg agg tca tcgc-3 0 ) was obtained from GeneTools, LLC. A 1 mM stock was used and diluted to 1:2 or 1:3 for injections into one-cell embyros. This morpholino is the same as one previously used (with the addition of two nucleotides at the 3 0 end) that resulted in a strong phenocopy of the neckless mutant in this concentration range (Begemann et al., 2001 ).
Cloning and characterization of the Raldh2 promoter
A BAC clone containing the raldh2 genomic region was sequenced starting with primers based upon the 5 0 cDNA sequences. Approximately 3.5 kb of DNA 5 0 to the initiation ATG was sequenced and 2.6 kb 5 0 to the initiating ATG was amplified using the polymerase chain reaction and subcloned into a pGEM-T vector (Promega). This fragment was then cloned into our pW1 vector (Balkan et al., 1992 ) and a firefly luciferase cloned downstream from the promoter. Culture of the zebrafish embryonic fibroblast ZF-4 cell line and zebrafish adult fibroblast AB.9 cell line (American Type Culture Collection), cell transfections with Lipofectamine (Invitrogen), and luciferase assays using the Dual Luciferase Reporter Assay System (Promega) were performed as described previously with the following exceptions (Lassiter et al., 2002) . In each well of the 12-well plate, 500 ng of the raldh2 promoter x luciferase construct, 100 ng of EF1a/ RAR2.B (Perz-Edwards et al., 2001) , and 100 ng of SV40-Renilla luciferase were transfected. Two hours after transfection, media containing DMSO or RA dissolved in DMSO was added (final DMSO concentration was 0.1% in each well). After 24 or 48 h, cell extracts were made and readings of firefly and renilla luciferase activities and a ratio of the two were measured using a Turner TD-20/20 Luminometer. Ratios of firefly/renilla activity for each sample were then converted to a percentage of the DMSO control. Calculations and graphing were performed in Microsoft Excel. Data were analyzed using an unpaired student's t test.
